Headquartered in Newtown Square, PA·Fiscal year ends September·NASDAQ: AVBP·arrivent.com
About ArriVent BioPharma
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated cancer medicines.
**Firmonertinib (lead candidate)**
- An oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations.
- Approved in China for several EGFR-mutant NSCLC indications.
- Holds U.S. FDA Breakthrough Therapy Designation (first-line EGFR exon 20 insertion NSCLC) and Orphan Drug Designation.
- Being studied in the global pivotal Phase 3 ALPACCA trial in first-line EGFR PACC-mutant NSCLC, conducted jointly with partner Allist.
- The Phase 3 FURVENT trial did not meet its primary PFS endpoint and is under review.
**Antibody-drug conjugate (ADC) pipeline**
- ARR-217 (MRG007): a CDH17-targeted, exatecan-based ADC for gastrointestinal cancers such as colorectal cancer, developed with Lepu Biopharma.
- ARR-002 (AV-P138-ADC): a first-in-class MUC16/NaPi2b dual-target tetravalent ADC in Phase 1a/1b for ovarian and endometrial cancers.
**Funding**
- The company recorded its first collaboration revenue in the third quarter of 2026.
- It funds operations primarily from cash and investments, which it expects to last to mid-2028. Updated
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated cancer medicines. **Firmonertinib (lead candidate)** - An oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against classical and uncommon EGFR mutations…
What is the AVBP stock price target?
The Wall Street consensus 12-month price target for AVBP is $26.40.